Avience Biomedicals Limited · NSE:AVIENCE
Avience Biomedicals — FY2026 Earnings Presentation
29 slides from Avience Biomedicals's earnings presentation, Jul 24, 2026
Slide 1: Regulation 30 intimation to NSE
July 24, 2026 The Manager (Listing), National Stock Exchange of India Limited, Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol: AVIENCE Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2
Slide 2: Investor Presentation
Ayr: Nbio” AVIENCE BIOMEDICALS LIMITED INVESTOR PRESENTATION
Slide 3: Disclaimer
This presentation has been prepared by Avience Biomedicals Limited solely for informational purposes. The information contained herein is intended to provide a general overview of the Company, its business operations, products, services, industry and growth strategy. It does not constitute an offer,
Slide 4: Manufacturing Facility
MANUFACTURING FACILITY 2019 88
Slide 5: Business Model
BUSINESS MODEL MANUFACTURING OF IVD Kits Reagents Consumables Diagnostic Products GOVERNMENT P~ TM pospirats Avience Biomedicals Limited DISTRIBUTION & STRATEGIC PARTNERSHIPS Pan India distribution network and strategic collaborations © | PLACEMENT OF DIAGNOSTIC INSTRUMENTS / ANALYZERS Installed at
Slide 6: Meet Our Team
MEET OUR TEAM sem Mr. Dharam Deo Choudhary Promoter & Managing Director (>) Educational background includes a Bachelor of Commerce and member of ICMAI. (>) 30 years of experience across accounts, finance, and business management with deep strategic and financial expertise. (>) 15-year tenure as Dire
Slide 7: Meet Our Team
MEET OUR TEAM @ Mrs. Deepa Choudhary Promoter & Executive Director > Aged 37 years, holds a Bachelor of Arts degree from Chhatrapati Shahu ji Maharaj University, Kanpur. > 5S years of experience in formulating and implementing strategic business development > Expert in market analysis, relationship
Slide 8: Product: IVD Kits
PRODUCT apy VD KITS © Diagnostic Test Kits © Screening Products Me \ \ ( REAGENTS = DIAGNOSTIC \ py - & INSTRUMENTS NOW « Biochemistry Reagents TF Fran Integrated Diagnostics & | Medical Devices [@) © Electrolyte Systems. © Automated Diagnostic =e, Sm Equipment = MOLECULAR DIAGNOSTICS X @ PCR Relate
Slide 9: Journey of Growth
JOURNEY OF GROWTH > © © OO @ 2019 2020 2022 2024 2025 2026+ Incorporation of Expansion of Strengthening Corporate Product & Regulatory Next Phase Avience Biomedicals Product Portfolio Manufacturing Milestone Expansion of Growth Capabilities ¢ Incorporated on IVD Kits ; © Conversion into Gong rte SAE
Slide 10: Manufactured Products - Complete Diagnostic Solutions
MANUFACTURED PRODUCTS - COMPLETE DIAGNOSTIC SOLUTIONS == Ayyvensic ——————————’) RAPID TEST KITS MOLECULAR po CULTUREMEDIA Avisure Pregnancy Card Avisure Pregnancy Strip Covid-19 Hid RTqPCR ASSAY HIN1 Swine Flu Viral Transport Solution —~ ae HINT Detection Kits au ELECTROLYTE ANALYZER & REAGENTS Avi
Slide 11: Manufacturing & Quality Control
MANUFACTURING & QUALITY CONTROL see Wy QZ Ii) TL mip ASSEMBLING PROCESS PACKAGING POUCHES FOR RAPID TEST KITS FOR RAPID TEST KITS load 7 ASSEMBLY OF QUALITY TESTING MACHINE BIOCHEMISTRY MACHINE FOR RAPID TEST KITS
Slide 12: Sept -
30.18 cr Sept - 26 15.95 Cr 88 Sept - 26 Oct - 26 Oct - 26
Slide 13: CDSCO Manufacturing License Process
CDSCO MANUFACTURING LICENSE PROCESS DOCUMENT COLLECTION Collation of documents for obtaining test license APPLICATION SUBMISSION TEST LICENSE ISSUED PRODUCT MANUFACTURING 6 PRODUCT TESTING > + kf + Za Submission of Issue of test application for license by test license CDSCO Manufacturing of the prod
Slide 14: CDSCO Licensed Product Portfolio
CDSCO LICENSED PRODUCT PORTFOLIO 88 CDSCO Manufacturing Licenses Across Multiple Diagnostic Categories BIOCHEMISTRY PRODUCTS RAPID DIAGNOSTIC TEST KITS Biochemistry Analyzers @ Dengue NSt & Combo Test a | : erst | wwe | HV Hestg = @_ Malaria PF/PV & Pf/Pan Test @ Probe Cleaner Glucose, Urea, Creatin
Slide 15: Customer & Distribution Network
CUSTOMER & DISTRIBUTION NETWORK News (oe PAN INDIA DISTRIBUTION PRESENCE g OUR CUSTOMER SEGMENTS EXPANDING REACH Me } @ 4) { ar ACROSS IMULTIPUEISTATES GOVERNMENT PRIVATE DIAGNOSTIC HOSPITALS HOSPITALS LABORATORIES STRONG DISTRIBUTION & CHANNEL NETWORK = Eo + 7 INSTITUTIONAL & Ne % HEALTHCARE FOCUSE
Slide 16: Industry Outlook
INDUSTRY OUTLOOK India's Diagnostics Industry Positioned for Strong Long Term Growth ° Indian diagnostics market — In vitro vs In vivo (INR B, FY20-30P) MARKET SNAPSHOT jae cAGR 964.3 (Syz035) veo) @ indian diagnostics market expected to reach ¥ 1,964 Billion by FY30P 1,131.3 11.5% 11.2% tv) IVD seg
Slide 17: Competitive Strengths
COMPETITIVE STRENGTHS MEENGiG 1] oO. BB secosco INTEGRATED ray ms) APPROVED CDSCO RECURRING MANUFACTURING & SF cag PRODUCTS CONSUMABLES- DISTRIBUTION ' Ss WITH STRONG LED REVENUE PLATFORM REGULATORY MODEL —— CAPABILITIES ——- CB stronc Ng 8 n= G INSTITUTIONAL = + EXPANSION Pe WELL POSITIONED PRESENCE
Slide 18: Investment Rationale
INVESTMENT RATIONALE Well Positioned to Capitalize on India’s Growing Diagnostics & Healthcare Opportunity ey fe | ere i | gr lee | ee fee Ue ‘ Diversified Portfolio 88 CDSCO Approvals Planned Product Expansion Pan-India Network Offering a comprehensive range of Strong regulatory credentials with Th
Slide 19: Certifications, Compliance & Quality Excellence
CERTIFICATIONS, COMPLIANCE & QUALITY EXCELLENCE Globally Recognized Standards. Quality Assured. Built for Trust. ‘cent Management ste fo: teal Devices 1. ISO 13485:2016 (IAF Mi Quality Management System for Medical Devices © IAF MLA Recognized @ International Medical Device ‘Quality Standard © Cover
Slide 20: Regulatory & Quality Excellence
REGULATORY & QUALITY EXCELLENCE B 88 cpsco 88 CATEGORIES REGULATORY APPROVAL JOURNEY Gf@r>x7 i> Mm > O> w ‘APPLICATION TESTING & DOCUMENTATION APPROVAL EVALUATION REVIEW Avience Biomedicals Limited | APPROVED PRODUCTS CDSCO 200+ APPLICATIONS UNDER PROCESS APPROVED PRODUCTS STRONG UNDERSTANDING OF RE
Slide 21: Way Forward
WAY FORWARD 1. EXPAND MANUFACTURING CAPACITY Expand Manufacturing Capacity through the upcoming fully automated Medical Device Park facility to support higher volumes and product diversification. 2. ACCELERATE PRODUCT APPROVALS & COMMERCIALIZATION Accelerate Product Approvals & Commercialization by
Slide 22: Future Outlook
FUTURE OUTLOOK Building the Next Phase of Growth 288+ Products Expanded Product Portfolio Target to expand to y 288+ approved products from 88+ currently rah —___—_———+ KEY GROWTH DRIVERS Commercialisation Expansion of Q product portfolio to of newly 288+ products approved products Scale-up through
Slide 23: Management Commentary
MANAGEMENT COMMENTARY (eae Mr. Dharam Deo Choudhary Promoter & Managing Director Avience Biomedicals Limited 66 FY26 has been a landmark year for Avience Biomedicals, marked by robust financial performance, successful completion of our IPO, and strong progress across our strategic growth initiatives
Slide 24: Financial Highlights
FINANCIAL HIGHLIGHTS Strong Growth. Improving Profitability. Consistent Performance. © (@ Lakhs) 6,000 5,000 4,000 3,000 2,000 1,000 REVENUE FROM OPERATIONS (% Lakhs ) +16.06% 4,523.59 wenn 5,250.58 Ee a FY25 FY26 7») VIZNbic® ‘Complete Healthcare Solution EBITDA PAT (% Lakhs ) ( % Lakhs ) (® Lakhs)
Slide 25: Financial Highlights: Margins and Returns
A VIZENbiC” ‘Complete Healthcare Solution FINANCIAL HIGHLIGHTS Strengthening Margins. Improving Returns. Consistent Value Creation. aii EBITDA MARGIN (%) 2) ROE (%) oF) ROCE (%) 35% 60% 35% 30% 28.45% a 49.89% aul 24.88% 25% J 25.35% 25% | 23.03% = ee = © 20% | z 32.37% R ony | 2 Lu 30% Ww = 15% g 1
Slide 26: Financial Highlights: Profit and Loss
7») VIZNbio” ‘Complete Healthcare Solution FINANCIAL HIGHLIGHTS Strong Growth. Improving Profitability. Consistent Performance. Consolidated Statement of Profit and Loss (= Lakhs) FY25 FY26 (Mar 31, 2025) (Mar 31, 2026) (All amounts in = Lakhs, unless otherwise stated) e: A. REVENUE ( I | Revenue fr
Slide 27: Balance Sheet Highlights
r») VIENbic® BALANCE SHEET HIGHLIGHTS Strengthening Financial Position Through Asset Expansion and Net Worth Growth. (® Lakhs) EQUITY & LIABILITIES FY25 FY26 ASSETS FY25 FY26 Particulars (@ Lakhs) (Mar 31, 2025) (Mar 31, 2026) Particulars (= Lakhs) (Mar 31, 2025) (Mar 31, 2026) 1. SHAREHOLDER’S FUND
Slide 28: Revenue Mix - Domestic vs Export
@ REVENUE MIX - DOMESTIC vs EXPORT =» AQviensio Strong Domestic Presence. Expanding Global Reach. Particulars ete piso Share (%) Share (%) @ Domestic 81.85% 98.99% @ Exports 18.15% 1.01% Tetalifevenuis 100.00% 00.00% from Operations contributing 98.99% in FY26, while exports contributed 1.01%. ©) |
Slide 29: Moonwalk Capital IR Team
Moonwalk Capital IR Team Phone: +917014618970 E-mail: investorrelations@moonwalkcapitaladvisors.com